

The investigational anti-reflux formula will be equivalent to the currently marketed control anti-reflux formula with regard to intestinal tolerance during eight weeks in infants with regurgitation.

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

Bron

NTR

Verkorte titel

PUP study

Aandoening

Infants with regurgitation

Ondersteuning

Primaire sponsor : Danone Research - Centre for Specialised Nutrition
Overige ondersteuning : Danone Research - Centre for Specialised Nutrition

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Occurrence and severity of intestinal tolerance characteristics.

Toelichting onderzoek

Achtergrond van het onderzoek

This study aims to investigate the impact of the renewed recipe compared to the currently marketed anti-reflux infant formula primarily on intestinal tolerance, and in addition on safety and efficacy of regurgitation. The study is designed as an equivalence trial of eight weeks with a run-in period on the control product for washing-out any confounding effects and will be conducted in regurgitating infants that are otherwise healthy.

Doel van het onderzoek

The investigational anti-reflux formula will be equivalent to the currently marketed control anti-reflux formula with regard to intestinal tolerance during eight weeks in infants with regurgitation.

Onderzoeksopzet

1. Screening;
2. Baseline;
3. 1-week call;
4. 2-week visit;
5. 4-week visit;
6. 8-week visit.

Onderzoeksproduct en/of interventie

Run-in period of 2 to 4 weeks on control product, followed by 8 weeks randomised on either investigational or control product. The investigational product is a renewed anti-reflux formula; the control product is the currently marketed anti-reflux formula.

Contactpersonen

Publiek

Danone Research,
P.O. Box 7005
C. Smeets
Wageningen 6700 CA
The Netherlands
+31 317 467 800

Wetenschappelijk

Danone Research,
P.O. Box 7005
C. Smeets
Wageningen 6700 CA
The Netherlands
+31 317 467 800

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Healthy term infants (37-42 weeks gestation at birth);
2. Age <= 3 months at screening;
3. >= 3 episodes of regurgitation/day at screening;
4. >= 75% formula feeding;
5. Parent's written informed consent;
6. Parent's willingness and ability to comply with the protocol requirements.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Clinically significant congenital disease including gastroesophageal, respiratory, and neurological disorders, (suspicion of) food allergies, and disease affecting normal growth;
2. Gastrointestinal infection within 4 weeks prior to randomisation;
3. Use within 4 weeks prior to randomisation and/or anticipated use during study of:
 - A. Probiotics;
 - B. Prebiotics (except for human milk);
 - C. Antibiotics;
 - D. Cisapride, metoclopramide, proton pump inhibitors, H2 receptor antagonists;
 - E. Anti-reflux formula (except for assigned study product);
 - F. Locust Bean Gum (e.g. Nutrilon Nutriton);
 - G. Weaning food including rice flour (restricted only during run-in and first 4-week investigational period);
 - H. Other investigational products.

Onderzoeksopzet

Opzet

Type :	Interventie onderzoek
Onderzoeksmodel :	Parallel
Toewijzing :	Gerandomiseerd
Blinding :	Dubbelblind
Controle :	Geneesmiddel

Deelname

Nederland	
Status :	Werving gestopt
(Verwachte) startdatum :	11-06-2009
Aantal proefpersonen :	98
Type :	Werkelijke startdatum

Ethische beoordeling

Positief advies

Datum : 08-06-2009

Soort : Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1732
NTR-old	NTR1842
Ander register	Danone Research B.V. : UAR 2 C/A
ISRCTN	ISRCTN wordt niet meer aangevraagd

Resultaten

Samenvatting resultaten

N/A